Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou
{"title":"持续的心血管危险因素控制与SLE中代谢功能障碍相关的脂肪变性肝病风险降低相关。","authors":"Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou","doi":"10.1093/rheumatology/keaf483","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Patients with SLE have a higher prevalence of cardiometabolic risk factors, metabolic syndrome and cardiovascular disease than the general population. The metabolic dysfunction-associated steatotic liver disease (MASLD), a new term for non-alcohol-related fatty liver disease, has been recognized as an independent predictor of cardiovascular events in the general population. However, the prevalence and associations of MASLD in SLE are uncertain. We aimed to investigate the potential association between MASLD and traditional and disease-related cardiovascular risk factors (CVRFs) in SLE.</p><p><strong>Methods: </strong>Patients with SLE and age- and sex-matched healthy control (HCs) who completed a 10-year carotid/femoral ultrasound follow-up examination were invited to undergo transient liver elastography (TEA) to assess MASLD prevalence based on international consensus criteria. Multivariate regression models examined associations between MASLD and the CVRF burden in past 10 years, including traditional and disease-related CVRFs, and atherosclerotic plaque progression.</p><p><strong>Results: </strong>TEA was performed in 77 SLE patients (median age: 53 years) and 45 age/sex-matched HCs with 10-year follow-up; 40% of patients and 44% of HCs met criteria for MASLD. In SLE, MASLD risk was reduced by 55% (odds ratio [OR]: 0.45, P = 0.021) for each additional sustainedly achieved traditional CVRF target (blood pressure, lipids, smoking, physical activity, or body weight). Patients with femoral plaque progression and consistent IgG anti-beta2glycoprotein I antibody positivity over the past 10 years had a 3.6-fold (OR: 3.62, P = 0.047) and 6.6-fold (OR: 6.58, P = 0.021) higher risk for MASLD, respectively.</p><p><strong>Conclusion: </strong>Femoral plaque progression and persistent IgG anti-beta2 glycoprotein I antibody positivity are independently associated with MASLD in SLE, while MASLD risk is halved for each additional CVRF target sustainedly attained.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustained cardiovascular risk factor control is associated with reduced metabolic dysfunction-associated steatotic liver disease risk in SLE.\",\"authors\":\"Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou\",\"doi\":\"10.1093/rheumatology/keaf483\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Patients with SLE have a higher prevalence of cardiometabolic risk factors, metabolic syndrome and cardiovascular disease than the general population. The metabolic dysfunction-associated steatotic liver disease (MASLD), a new term for non-alcohol-related fatty liver disease, has been recognized as an independent predictor of cardiovascular events in the general population. However, the prevalence and associations of MASLD in SLE are uncertain. We aimed to investigate the potential association between MASLD and traditional and disease-related cardiovascular risk factors (CVRFs) in SLE.</p><p><strong>Methods: </strong>Patients with SLE and age- and sex-matched healthy control (HCs) who completed a 10-year carotid/femoral ultrasound follow-up examination were invited to undergo transient liver elastography (TEA) to assess MASLD prevalence based on international consensus criteria. Multivariate regression models examined associations between MASLD and the CVRF burden in past 10 years, including traditional and disease-related CVRFs, and atherosclerotic plaque progression.</p><p><strong>Results: </strong>TEA was performed in 77 SLE patients (median age: 53 years) and 45 age/sex-matched HCs with 10-year follow-up; 40% of patients and 44% of HCs met criteria for MASLD. In SLE, MASLD risk was reduced by 55% (odds ratio [OR]: 0.45, P = 0.021) for each additional sustainedly achieved traditional CVRF target (blood pressure, lipids, smoking, physical activity, or body weight). Patients with femoral plaque progression and consistent IgG anti-beta2glycoprotein I antibody positivity over the past 10 years had a 3.6-fold (OR: 3.62, P = 0.047) and 6.6-fold (OR: 6.58, P = 0.021) higher risk for MASLD, respectively.</p><p><strong>Conclusion: </strong>Femoral plaque progression and persistent IgG anti-beta2 glycoprotein I antibody positivity are independently associated with MASLD in SLE, while MASLD risk is halved for each additional CVRF target sustainedly attained.</p>\",\"PeriodicalId\":21255,\"journal\":{\"name\":\"Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/keaf483\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keaf483","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:SLE患者的心脏代谢危险因素、代谢综合征和心血管疾病的患病率高于一般人群。代谢功能障碍相关脂肪变性肝病(MASLD)是一种非酒精相关性脂肪性肝病的新术语,已被认为是普通人群心血管事件的独立预测因子。然而,SLE中MASLD的患病率和相关性尚不确定。我们的目的是研究SLE中MASLD与传统和疾病相关心血管危险因素(cvrf)之间的潜在关联。方法:邀请完成10年颈动脉/股动脉超声随访检查的SLE患者和年龄和性别匹配的健康对照(hcc)进行短暂肝弹性成像(TEA),根据国际共识标准评估MASLD的患病率。多元回归模型检验了过去10年MASLD与CVRF负担之间的关系,包括传统的和疾病相关的CVRF,以及动脉粥样硬化斑块进展。结果:TEA在77例SLE患者(中位年龄:53岁)和45例年龄/性别匹配的hcc中进行了10年随访;40%的患者和44%的hcc符合MASLD的标准。在SLE中,每增加一个持续达到传统CVRF目标(血压、血脂、吸烟、体力活动或体重),MASLD风险降低55%(优势比[OR]: 0.45, P = 0.021)。在过去10年中,股骨斑块进展和IgG抗β 2糖蛋白I抗体持续呈阳性的患者发生MASLD的风险分别增加3.6倍(OR: 3.62, P = 0.047)和6.6倍(OR: 6.58, P = 0.021)。结论:股骨斑块进展和持续的IgG抗β 2糖蛋白I抗体阳性与SLE患者的MASLD独立相关,而每增加一个CVRF目标,MASLD的风险就会减半。
Sustained cardiovascular risk factor control is associated with reduced metabolic dysfunction-associated steatotic liver disease risk in SLE.
Objectives: Patients with SLE have a higher prevalence of cardiometabolic risk factors, metabolic syndrome and cardiovascular disease than the general population. The metabolic dysfunction-associated steatotic liver disease (MASLD), a new term for non-alcohol-related fatty liver disease, has been recognized as an independent predictor of cardiovascular events in the general population. However, the prevalence and associations of MASLD in SLE are uncertain. We aimed to investigate the potential association between MASLD and traditional and disease-related cardiovascular risk factors (CVRFs) in SLE.
Methods: Patients with SLE and age- and sex-matched healthy control (HCs) who completed a 10-year carotid/femoral ultrasound follow-up examination were invited to undergo transient liver elastography (TEA) to assess MASLD prevalence based on international consensus criteria. Multivariate regression models examined associations between MASLD and the CVRF burden in past 10 years, including traditional and disease-related CVRFs, and atherosclerotic plaque progression.
Results: TEA was performed in 77 SLE patients (median age: 53 years) and 45 age/sex-matched HCs with 10-year follow-up; 40% of patients and 44% of HCs met criteria for MASLD. In SLE, MASLD risk was reduced by 55% (odds ratio [OR]: 0.45, P = 0.021) for each additional sustainedly achieved traditional CVRF target (blood pressure, lipids, smoking, physical activity, or body weight). Patients with femoral plaque progression and consistent IgG anti-beta2glycoprotein I antibody positivity over the past 10 years had a 3.6-fold (OR: 3.62, P = 0.047) and 6.6-fold (OR: 6.58, P = 0.021) higher risk for MASLD, respectively.
Conclusion: Femoral plaque progression and persistent IgG anti-beta2 glycoprotein I antibody positivity are independently associated with MASLD in SLE, while MASLD risk is halved for each additional CVRF target sustainedly attained.
期刊介绍:
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.